Skip to main content
  • Females Saw Greater Weight Loss Than Men in STEP-HFpEF Program: Secondary Analysis

    Female patients with heart failure with preserved ejection fraction (HFpEF) on the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide saw a greater reduction in bodyweight than male counterparts in the STEP-HFpEF trials, with otherwise similar treatment benefits, according to a secondary analysis of the program.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details